Pharmaceutical & Biotechnology Market Next Big Thing | Major Giants- Diabetes, Ophthalmology HCV, Atrial Fibrillation

HTF MI added a new research study in its database with title 'Global Pharmaceutical & Biotechnology Outlook: Global Pharma' that includes detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes regions like North America, South America, Asia-pacific, Europe and important players/vendors such as Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia etc.The report will help user gain market insights, future trends and growth prospects for forecast period of 2020-2026.

Request a sample report @ https://www.htfmarketreport.com/sample-report/2827054-global-pharmaceutical-biotechnology-outlook

Summary
Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer’s and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care. The year 2012 has marked the beginning of this trend as many new blockbuster drug were approved and we also witnessed promising proof of concept data on many of the potential path breaking innovation. There are also major outcome clinical trials that will deliver data over the next few years and if positive, we will see the change in fortunes of many existing drugs that are on the market.

In the near term as well the sector continues to remain attractive, as cost containment initiatives, restructuring/deconsolidation, share repurchase program, M&A, emerging market growth potential and dividend policy continue to be encouraging. Over the next few years, the growth of the industry would be shaped up by a battle between fundamental growth drivers (Value added innovation) versus regulatory pressures to contain costs.

Global Biopharmaceutical Outlook 2013-Large Cap Pharma, released by MP Advisors provides analyses of individual large cap companies, promising drug candidates in their late stage pipelines, competitive landscape, and important therapy areas where new innovation will create leadership, forecast for major marketed drugs where competition/ regulatory scenario will change the dynamics, and the potential impact of several important upcoming milestones on the industry.

Place a Purchase Order For Market Study (Single User License) at: https://www.htfmarketreport.com/buy-now?format=1&report=2827054

Key Topics Covered
Value Based Pricing- Strength of Innovation Vs Fiscal Pressures
Major therapy areas to shape up pharma business going forward
Europe – Regulatory Pressures and Increasing Pro Generic Stance
Will US fall to Pricing Pressures?

Emerging Markets and their importance in Growth of Large Cap Pharma
Global Pharma -Drugs Losing Patent Protection By 2017
Impact of patent expiry in w.r.t. 2012 total revenue thru 2017
Global Pharma Research Pipeline (PhII And PhIII)- 2013
Global Pharma Milestones in 2013
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/2827054-global-pharmaceutical-biotechnology-outlook
Roche: Breast Cancer Franchise And Actemra To Drive Near Term Growth, And Multiple Blockbusters In Pipeline To Take Care Of Long Term Growth
GlaxoSmithKline: Next Generation Bronchodilators, Melanoma, Hiv And Emerging Market To Lead The Way While Regulatory Overhang In Respiratory And EU Pricing Pressure Persist
Bristol-Myers Squibb: Pressures To Dominate In The Near Term, Pipeline Will Take Longer To Deliver
AstraZeneca: 2013 Will Be A Transition Year And AZN May Have To Take Some Bold Initiatives
Eli Lilly: Late Stage Pipeline Fickle And Risky
Merck: News-flow from Mega-trial on MRK’s cardiology Franchise would reshape Merck’s Growth Prospects

Novartis: Back on a Growth Trajectory
Novo Nordisk: Hemophilia Franchise and Thrice Weekly Degludec – The Future Drivers
Pfizer: M&A Only Can Drive Further Upside In The Near Term
Sanofi: Solid Base Business, But Upside From Pipeline Will Take Longer To Come About
Global Pharma Sector Industry Tables

Over the next five years, we will witness surge in approval of new drugs that would deliver a major improvement in the standard of care. Therapy areas - Oncology, Diabetes, Ophthalmology HCV, Atrial Fibrillation, Multiple Sclerosis, Dyslipidemia, Alzheimer’s and Melanoma are few select areas where newer therapies that are safer and more efficacious will reach the market. Many of these innovations promise a paradigm shift in the standard of care. The year 2012 has marked the beginning of this trend as many new

....Continued

View Detailed Table of Content @ https://www.htfmarketreport.com/reports/2827054-global-pharmaceutical-biotechnology-outlook

Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at LinkedIn | Facebook | Twitter

HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

This release was published on openPR.